Vida Ventures, a next-generation life sciences venture firm, has closed its Vida Ventures II, raising $600 million in an oversubscribed fund.
Vida II will be used to further the firm’s life sciences platform, which began building a successful track record of investing with its inaugural fund by focusing on companies that change the paradigm of care for patients.
“Life sciences has become one of the most dynamic industries and a focal point for venture firms,” said Arie Belldegrun, M.D., FACS, co-founder and senior managing director.
Vida II fund investors include members of the Vida team, investors from the inaugural fund, top-tier endowments, foundations, family offices, funds-of-funds, and notable individuals across the United States and overseas.
With the close of Vida II, Vida has approximately $1 billion under management in less than two years since its inception.